Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study

Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study

Clinical studies treating pediatric and adult solid tumors, such as glioblastoma (GBM), with a triple-drug regimen of temozolomide (TMZ), bevacizumab (BEV), and irinotecan (IRI) [TBI] have demonstrated various efficacies, but with no unexpected toxicities. The TBI regimen has never been studied in r...

Full description

Bibliographic Details
Main Authors: Guangrong Lu, Mayank Rao, Ping Zhu, Buqing Liang, Rasheda T. El-Nazer, Ekokobe Fonkem, Meenakshi B. Bhattacharjee, Jay-Jiguang Zhu
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-01-01
Series:Frontiers in Neurology
Subjects:
recurrent glioblastoma (rGBM)
temozolomide
bevacizumab
irinotecan
tumor treating fields (TTFields, Optune)
chemotherapy
Online Access:https://www.frontiersin.org/article/10.3389/fneur.2019.00042/full

Internet

https://www.frontiersin.org/article/10.3389/fneur.2019.00042/full

Similar Items